# Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

> **NCT05092412** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **You Lu** · enrollment: 30 (actual)

## Conditions studied

- Lung Cancer
- Extensive-stage Small-cell Lung Cancer
- Durvalumab

## Interventions

- **RADIATION:** Low-dose radiotherapy
- **DRUG:** Durvalumab
- **DRUG:** Etoposide, and cisplatin/carboplatin

## Key facts

- **NCT ID:** NCT05092412
- **Lead sponsor:** You Lu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2023-02-06
- **Final completion:** 2027-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05092412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05092412, "Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT05092412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*